IMPACT OF NEUROTROPIC VIRUSES ON SURVIVAL OF PATIENTS WITH SURGICALLY TREATED GLIOBLASTOMA

Acta Clin Croat. 2022 Nov;61(3):476-481. doi: 10.20471/acc.2022.61.03.12.

Abstract

Introduction: Glioblastoma represents the most aggressive tumor of the brain with an estimated survival rate of twelve to fifteen months after the primary diagnosis. The role of neurotropic viruses in pathogenesis of the tumor has remained unclear to date. During the last two decades, many studies were conducted with the aim of confirming viral influence in the development of glioblastoma.

Methods: We conducted a retrospective study in a time period of five years using formalin-fixed paraffin-embedded tissues of glioblastoma. Immunohistochemistry was performed for three viruses: CMV, EBV and HSV-1, using an automated staining system.

Results: Mean age of patients in our group was 66.7±8.5 years. A slight male dominance was noted. Negative immunohistochemistry results were obtained for CMV and EBV, which were excluded from further investigation. Based on IRS score, we confirmed six HSV-1 samples which were rated as IRS score 2. Five more samples of HSV-1 were rated as IRS score 1 and were excluded from the study.

Conclusion: According to our retrospective study and its results, we found no impact of neurotropic viruses in the survival rate of glioblastoma. Further studies should be conducted including a wider range of viral detection methods.

Keywords: antibodies; brain neoplasms; cytomegalovirus; glioblastoma; herpes simplex.

MeSH terms

  • Aged
  • Cytomegalovirus
  • Cytomegalovirus Infections*
  • Glioblastoma* / pathology
  • Glioblastoma* / surgery
  • Herpesvirus 1, Human*
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Viruses*